PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies

CONCLUSIONS: PAR4 antagonism has additive antithrombotic effects when used in addition to ticagrelor, aspirin, or their combination, in patients with stable coronary heart disease.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05093790.PMID:38357820 | DOI:10.1161/ATVBAHA.123.320448

Source: Arteriosclerosis, Thrombosis and Vascular Biology - February 15, 2024 Category: Cardiology Authors: Jennifer Nash Mohammed N Meah Beth Whittington Samuel Debono Jennifer Raftis Mark R Miller Andrew Sorbie Nicholas L Mills Josselin Nespoux Lorraine Bruce Rodger Duffin Neeraj Dhaun Mairi Brittan Longfei Chao Samira Merali Minji Kim Zhaoqing Wang Yue Zhang Source Type: research